Blood Pressure Control with a Single-Pill Combination of Indapamide Sustained-Release and Amlodipine in Patients with Hypertension: The EFFICIENT Study
Objective Despite antihypertensive treatment, most hypertensive patients still have high blood pressure (BP), notably high systolic blood pressure (SBP). The EFFICIENT study examines the efficacy and acceptability of a single-pill combination of sustained-release (SR) indapamide, a thiazide-like diuretic, and amlodipine, a calcium channel blocker (CCB), in the management of hypertension. Methods Patients who were previously uncontrolled on CCB monotherapy (BP≥140/90 mm Hg) or were previously untreated with grade 2 or 3 essential hypertension (BP≥160/100 mm Hg) received a single-pill combination tablet containing indapamide SR 1.5 mg and amlodipine 5 mg daily for 45 days, in this multicenter prospective phase 4 study. The primary outcome was mean change in BP from baseline; percentage of patients achieving BP control (BP<140/90 mm Hg) was a secondary endpoint. SBP reduction (ΔSBP) versus diastolic BP reduction (ΔDBP) was evaluated (ΔSBP/ΔDBP) from baseline to day 45. Safety and tolerability were also assessed. Results Mean baseline BP of 196 patients (mean age 52.3 years) was 160.2/97.9 mm Hg. After 45 days, mean SBP decreased by 28.5 mm Hg (95% CI, 26.4 to 30.6), while diastolic BP decreased by 15.6 mm Hg (95% CI, 14.5 to 16.7). BP control (<140/90 mm Hg) was achieved in 85% patients. ΔSBP/ΔDBP was 1.82 in the overall population. Few patients (n = 3 [2%]) reported side effects, and most (n = 194 [99%]) adhered to treatment. Conclusion In patients who were previously uncontrolled on CCB monotherapy or untreated with grade 2 or 3 hypertension, single-pill combination indapamide SR/amlodipine reduced BP effectively—especially SBP— over 45 days, and was safe and well tolerated. Trial Registration Clinical Trial Registry – India CTRI/2010/091/000114
References
[1]
Turnbull F (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 362: 1527–1535.. doi: 10.1016/s0140-6736(03)14739-3
[2]
Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, et al. (2008) Treatment of hypertension in Patients 80 years of Age or Older. N Engl J Med 358: 1887–1898.. doi: 10.1056/nejmoa0801369
[3]
Collins R, Peto R (1994) Antihypertensive drug therapy: effects on stroke and coronary heart disease. In: Swales JD, eds. Textbook of Hypertension. Oxford, UK: Blackwell Scientific Publications; 1156–1164.
[4]
Mohan V, Deepa M, Farooq S, Datta M, Deepa R (2007) Prevalence, awareness and control of hypertension in Chennai–The Chennai Urban Rural Epidemiology Study (CURES-52). J Assoc Physicians India 55: 326–332.. doi: 10.1007/s00125-006-0219-2
[5]
Tocci G, Rosei EA, Ambrosioni E, Borghi C, Ferri C, et al. (2012) Blood pressure control in Italy: analysis of clinical data from 2005–2011 surveys on hypertension. J Hypertens 30: 1065–1074.. doi: 10.1097/hjh.0b013e3283535993
[6]
Williams B, Lindholm LH, Sever P (2008) Systolic pressure is all that matters. Lancet 371: 2219–2221.. doi: 10.1016/s0140-6736(08)60804-1
[7]
Corrao G, Nicotra F, Parodi A, Zambon A, Heiman F, et al. (2011) Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension 58: 566–572.. doi: 10.1161/hypertensionaha.111.177592
[8]
Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, et al. (2012) Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 59: 1124–1131.. doi: 10.1161/hypertensionaha.112.194167
[9]
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, et al. (2007) 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 28: 1462–1536.. doi: 10.1097/hjh.0b013e3281fc975a
[10]
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, et al. (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206–1252.. doi: 10.1161/01.hyp.0000107251.49515.c2
[11]
Guide to management of hypertension 2008: assessing and managing raised blood pressure in adults. Updated December 2010. Available: http:/heartfoundation.org.au/SiteCollect？ionDocument/HypertensionGuidelines2008to？2010Update.pdf. Accessed 2-1-22013.
[12]
Gupta AK, Arshad S, Poulter NR (2010) Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 55: 399–407.. doi: 10.1161/hypertensionaha.109.139816
[13]
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, et al. (2013) 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34: 2159–2219.. doi: 10.3109/08037051.2014.868629
[14]
Liu L, Zhang Y, Liu G, Li W, Zhang X, et al. (2005) The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 23: 2157–2172.. doi: 10.1097/01.hjh.0000194120.42722.ac
[15]
Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, et al. (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363: 2022–2031.. doi: 10.1016/s0140-6736(04)16451-9
[16]
Mulatero P, Verhovez A, Morello F, Veglio F (2007) Diagnosis and treatment of low-renin hypertension. Clin Endocrinol (Oxf) 67: 324–334.. doi: 10.1111/j.1365-2265.2007.02898.x
[17]
Baguet JP, Legallicier B, Auquier P, Robitail S (2007) Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Clin Drug Invest 27: 735–753.. doi: 10.2165/00044011-200727110-00001
[18]
Zhang Y, Agnoletti D, Safar ME, Blacher J (2011) Effect of antihypertensive agents on blood pressure variability: the Natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study. Hypertension 58: 155–160.. doi: 10.1161/hypertensionaha.111.174383
[19]
Wang JG, Li Y, Franklin SS, Safar M (2007) Prevention of stroke and myocardial infarction by amlodipine and angiotensin receptor blockers: A quantitative overview. Hypertension 50: 181–188.. doi: 10.1161/hypertensionaha.107.089763
[20]
van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, et al. (2012) Angiotensin-converting enzyme inhibitors reduce mortality in hypertension : a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone-system inhibitors involving 158,998 patients. Eur Heart J 33: 2088–2097.. doi: 10.1093/eurheartj/ehs075
[21]
Thomas F, Pannier B, Safar ME (2012) Impact of country of birth on arterial function in subjects living in France. J Am Soc Hypertens 6: 405–413.. doi: 10.1016/j.jash.2012.10.003
[22]
Franklin SS, Jacobs MJ, Wong ND, L'Italien GJ, Lapuerta P (2001) Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 37: 869–874.. doi: 10.1161/01.hyp.37.3.869
[23]
Salerno CM, Demopoulos L, Mukherjee R, Gradman AH (2004) Combination angiotensin receptor blocker/hydrochlorothiazide as initial therapy in the treatment of patients with severe hypertension. J Clin Hypertens (Greenwich) 6: 614–620.. doi: 10.1111/j.1524-6175.2004.03808.x
[24]
Pool JL, Glazer R, Weinberger M, Alvarado R, Huang J, et al. (2007) Comparison of valsartan/hydrochlorothiazide combination therapy at doses up to 320/25 mg versus monotherapy: a double-blind, placebo-controlled study followed by long-term combination therapy in hypertensive adults. Clin Ther 29: 61–73.. doi: 10.1016/j.clinthera.2007.01.007
[25]
Calhoun DA, Glazer RD, Pettyjohn FS, Coenen PD, Zhao Y, et al. (2008) Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension. Curr Med Res Opin 24: 2303–2311.. doi: 10.1185/03007990802271946
[26]
McManus RJ, Caulfield M, Williams B (2012) NICE hypertension guideline 2011: evidence based evolution. BMJ 344: e181. doi: 10.1136/bmj.e181
[27]
Moore RA, Seki T, Oheim K (1977) Antihypertensive action of indapamide and review of pharmacology and toxicology. Curr Med Res Opin 5: 25–32.. doi: 10.1185/03007997709110220
[28]
Waeber B, Rotaru C, Feihl F (2012) Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy. Expert Opin Pharmacother 13: 1515–1526.. doi: 10.1517/14656566.2012.698611
[29]
Ferrari R (1997) Major differences among the three classes of calcium antagonists. Eur Heart J 18 Suppl A: A56–A70.. doi: 10.1093/eurheartj/18.suppl_a.56
[30]
Seidel CL, Bohr DF (1971) Calcium and vascular smooth muscle contraction. Circ Res 28 Suppl-95. doi: 10.1161/01.res.28.5.ii-88
[31]
Mallion JM, Asmar R, Ambrosioni E, Macmahon M, Coupez JM, et al. (1996) [Evaluation of trough:peak ratio of indapamide 1.5 mg sustained-release form assessed by ambulatory blood pressure monitoring ]. Arch Mal Coeur Vaiss 89: 27–38..
[32]
Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, et al. (2011) Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial. J Hypertens 29: 1649–1659.. doi: 10.1097/hjh.0b013e328348345d
[33]
Taddei S (2012) Fixed-dose combination therapy in hypertension: pros. High Blood Press Cardiovasc Prev 19: 55–57.. doi: 10.1007/bf03262454
[34]
Gustafsson D (1987) Microvascular mechanisms involved in calcium antagonist edema formation. J Cardiovasc Pharmacol 10 Suppl 1: S121–S131.. doi: 10.1097/00005344-198710001-00023
[35]
Makani H, Bangalore S, Romero J, Htyte N, Berrios RS, et al. (2011) Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate–a meta-analysis of randomized trials. J Hypertens 29: 1270–1280.. doi: 10.1097/hjh.0b013e3283472643
[36]
Arguedas JA, Leiva V, Wright JM (2013) Blood pressure targets for hypertension in people with diabetes mellitus. Cochrane Database Syst Rev 10: CD008277. doi: 10.1002/14651858.cd008277.pub2
[37]
Wheeler DC, Becker GJ (2013) Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease? Kidney Int 83: 377–383.. doi: 10.1038/ki.2012.425
[38]
Law MR, Morris JK, Wald NJ (2009) Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338: b1665. doi: 10.1136/bmj.b1665
